To the full analysis
Buyback calculator for Summit Therapeutics
Summit Therapeutics stock: key metrics
SMMTMargins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 70.6% | −423.8% | −292.1% |
| 2007 | 1.9% | −388.5% | −334.1% |
| 2008 | 97.8% | −7,198.9% | −12,109.6% |
| 2009 | −706.9% | −3,047.6% | −1,769.2% |
| 2010 | 41.2% | −1,270.0% | −1,004.6% |
| 2011 | 82.9% | −422.3% | −379.0% |
| 2012 | 100.0% | −241.5% | −223.0% |
| 2013 | 98.7% | −363.8% | −330.4% |
| 2014 | 100.0% | −647.9% | −603.0% |
| 2015 | 96.0% | −1,588.3% | −1,572.0% |
| 2016 | 97.4% | −1,046.0% | −899.5% |
| 2017 | 99.3% | −182.3% | −142.3% |
| 2018 | 98.8% | 9.4% | 19.0% |
| 2020 | 100.0% | −11,392.7% | −6,127.6% |
| 2021 | 100.0% | −4,764.3% | −4,897.8% |
| 2022 | 100.0% | −10,225.4% | −11,174.8% |
| 2023 | no data | no data | no data |
| 2024 | no data | no data | no data |
| 2025 | no data | no data | no data |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −14.8% | −15.5% | −12.8% |
| 2007 | −37.2% | −87.3% | −29.0% |
| 2008 | −100.0% | −64.3% | −100.0% |
| 2009 | −40.4% | −42.5% | −29.1% |
| 2010 | −100.0% | −65.1% | −92.1% |
| 2011 | −100.0% | −72.7% | −69.1% |
| 2012 | −93.8% | −84.1% | −61.1% |
| 2013 | −77.6% | −78.8% | −50.6% |
| 2014 | −58.3% | −58.9% | −39.0% |
| 2015 | −87.9% | −58.5% | −56.4% |
| 2016 | 200.0% | −60.9% | −45.5% |
| 2017 | 200.0% | −51.7% | −25.8% |
| 2018 | 19.5% | 10.0% | 13.7% |
| 2020 | −66.3% | no data | −51.4% |
| 2021 | −100.0% | −79.9% | −78.2% |
| 2022 | −62.2% | −36.6% | −11.9% |
| 2023 | −100.0% | no data | −100.0% |
| 2024 | −56.9% | −62.0% | −50.8% |
| 2025 | −100.0% | no data | −100.0% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2020)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.